Miyazaki N, Iwasaki T, Sakai H, et al. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Curr Med Res Opin. 2024
Terada Mitsuo, Ito Aki, Kikawa Yuichiro, Koizumi Kei, Naito Yoichi, Shimoi Tatsunori, Ishihara Mikiya, Yamanaka Takashi, Ozaki Yukinori, Hara Fumikata, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast cancer (Tokyo, Japan). 2023. 30. 6
Masuda Hiroko, Tanabe Yuko, Sakai Hitomi, Matsumoto Koji, Shimomura Akihiko, Doi Mihoko, Miyoshi Yasuo, Takahashi Masato, Sagara Yasuaki, Tokunaga Shinya, et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast (Edinburgh, Scotland). 2023. 71. 22-28
Masuda Jun, Sakai Hitomi, Tsurutani Junji, Tanabe Yuko, Masuda Norikazu, Iwasa Tsutomu, Takahashi Masato, Futamura Manabu, Matsumoto Koji, Aogi Kenjiro, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). Journal for immunotherapy of cancer. 2023. 11. 9. e007126-e007126
Hitomi Sakai, et al. Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer. Journal of Clinical Gynecology & Obstetrics. 2023. 12. 2. 59-64
Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, et al. Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients. CANCER RESEARCH. 2022. 82. 4
Yoshio Itani, Hitomi Sakai, Mikiko Asai-Sato, Shinya Sato, Masayuki Futagami, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Tetsutaro Hamano, Yoshio Yoshida. A post-hoc study of relative dose intensity in elderly patients with advanced ovarian cancer (JGOG3016-A3). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)
(第21回日本臨床腫瘍学会 2024)
WJOG (West Japan Oncology Group) 乳癌コン センサス会議 2023
(第21回日本臨床腫瘍学会 2024)
Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B
(第21回日本臨床腫瘍学会 2024)
A randomized, double-blind, placebo-controlled study of olanzapine for CINV during T-DXd in HER2 positive metastatic breast cancer patients: WJOG14320B (ERICA)
(GBCC 2023)
HER2+ mBC患者を対象としたT-DXd投与中のCINVに対するオランザピン投与の第II相試験 WJOG14320B(ERICA)(Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA))
(日本乳癌学会総会プログラム抄録集 2022)
